CLAIMS

1. Use of nemolizumab in the preparation of a medicament for the treatment of atopic dermatitis in a subject having one or more moderate to severe skin excoriations, in which the skin excoriations have been assigned a score of at least 2 on the SCORAD scale.

2. Use according to Claim 1, in which the skin excoriations are moderate.

3. Use according to Claim 1, in which the skin excoriations are severe.

4. Use according to Claim 1, 2 or 3, in which the skin excoriations have been assigned a score of at least 3 on the SCORAD scale.

5. Use according to any preceding claim, in which the medicament comprises 30 mg to 60 mg of nemolizumab.

6. Use according to any preceding claim, in which the medicament is formulated for topical or parenteral administration.

7. Use according to any preceding claim, in which the medicament is formulated for subcutaneous administration.

8. Use according to any preceding claim, in which the medicament is to be administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

9. Use of nemolizumab in the preparation of a medicament for improving sleep quality in a subject suffering from atopic dermatitis and having one or more moderate to severe skin excoriations, in which the skin excoriations have been assigned a score of at least 2 on the SCORAD scale.

10. Use according to Claim 9, in which the skin excoriations are moderate.

11. Use according to Claim 9, in which the skin excoriations are severe.

12. Use according to Claim 9, 10 or 11, in which the skin excoriations have been assigned a score of at least 3 on the SCORAD scale.

13. Use according to any of Claims 9 to 12, in which the medicament comprises 30 mg to 60 mg of nemolizumab.

14. Use according to any of Claims 9 to 13, in which the medicament is formulated for topical or parenteral administration.

15. Use according to any of Claims 9 to 14, in which the medicament is formulated for subcutaneous administration.

16. Use according to any of Claims 9 to 15, in which the medicament is to be administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

17. Use according to any of Claims 9 to 16, in which an improvement of sleep quality is determined by detecting an improvement in one or more of: time of sleep onset latency, total sleep time, sleep efficiency, or time of waking after sleep onset.

18. Use according to any preceding claim, in which the medicament comprises 30 mg or 60 mg of nemolizumab and is formulated for subcutaneous administration.